Question 1

What are GLP-1 medications?

Accepted Answer

GLP-1 (glucagon-like peptide-1) medications are a class of drugs that mimic natural gut hormones to reduce appetite, slow digestion, and help regulate blood sugar. Popular GLP-1 medications for weight loss include semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound). These medications have shown remarkable effectiveness, with patients losing 15-25% of their body weight in clinical trials.

Question 2

How much weight can I expect to lose with semaglutide?

Accepted Answer

Clinical trials show that patients using semaglutide (Wegovy) lose an average of 15-17% of their body weight over 68 weeks. Individual results vary based on factors like starting weight, diet, exercise, and medication adherence. Many patients begin seeing results within the first month, with weight loss typically continuing for 12-18 months.

Question 3

What are the common side effects of GLP-1 medications?

Accepted Answer

The most common side effects include nausea, diarrhea, constipation, stomach pain, and decreased appetite. These effects are usually mild to moderate and often improve within 4-8 weeks as your body adjusts. The gradual dose increase schedule is designed to minimize side effects. Serious side effects are rare but can include pancreatitis and gallbladder issues.

Question 4

How much do GLP-1 weight loss treatments cost?

Accepted Answer

Costs vary widely depending on the medication, provider, and insurance coverage. Brand-name medications like Wegovy retail for $1,300-1,500/month without insurance. Medical weight loss clinics typically charge $300-800/month for comprehensive programs including medication. Some clinics offer compounded semaglutide at lower costs. Always verify insurance coverage and ask about payment plans.

Question 5

Do I need a prescription for semaglutide or tirzepatide?

Accepted Answer

Yes, all GLP-1 medications require a prescription from a licensed healthcare provider. You cannot legally purchase these medications without a prescription. Medical weight loss clinics can evaluate your eligibility, prescribe appropriate medications, and provide ongoing monitoring. Many clinics offer telehealth consultations for convenience.

Question 6

What is the difference between telehealth and in-person clinics?

Accepted Answer

Telehealth clinics offer virtual consultations, remote monitoring, and medication delivery to your home. They are convenient for busy schedules and rural areas. In-person clinics provide face-to-face consultations, on-site lab work, and additional services like body composition analysis. Many patients prefer telehealth for convenience, while others value the personal connection of in-person care.

Question 7

How do I find a reputable GLP-1 weight loss clinic?

Accepted Answer

Look for clinics with licensed medical providers (MDs, DOs, NPs, PAs), positive patient reviews, transparent pricing, and comprehensive care including follow-up appointments. Verify their credentials, ask about their experience with GLP-1 medications, and ensure they provide proper medical oversight. Our directory features verified clinics that meet quality standards.

Question 8

Can I use GLP-1 medications if I have diabetes?

Accepted Answer

Some GLP-1 medications like Ozempic and Mounjaro are FDA-approved for type 2 diabetes and can help with both blood sugar control and weight loss. However, dosing and monitoring may differ from weight-loss-only protocols. If you have diabetes, it is essential to work with a provider who can coordinate your diabetes management with weight loss treatment.

Question 9

How long do I need to take GLP-1 medications?

Accepted Answer

GLP-1 medications are typically used long-term for weight maintenance. Studies show that stopping the medication often leads to weight regain. Your provider will help determine the best approach for your situation, which may include continued medication at a maintenance dose, lifestyle modifications, or a combination approach.

Question 10

Are GLP-1 medications safe?

Accepted Answer

GLP-1 medications have been extensively studied and are FDA-approved with established safety profiles. They are generally safe for most adults when prescribed and monitored by qualified healthcare providers. However, they are not suitable for everyone, including those with certain medical conditions, pregnant women, or individuals with a history of medullary thyroid cancer. A thorough medical evaluation is essential before starting treatment.

Question 11

What is the difference between Wegovy and Ozempic?

Accepted Answer

Wegovy and Ozempic both contain the same active ingredient, semaglutide, and are both manufactured by Novo Nordisk. The key differences are in dosing and FDA-approved indications. Ozempic is approved for type 2 diabetes at doses up to 2.0 mg weekly, while Wegovy is approved for chronic weight management at the higher dose of 2.4 mg weekly. Wegovy was approved by the FDA on June 4, 2021, specifically for weight loss. While some providers prescribe Ozempic off-label for weight loss, Wegovy is the FDA-approved option for that purpose.

Question 12

What is the difference between Zepbound and Mounjaro?

Accepted Answer

Zepbound and Mounjaro both contain tirzepatide and are manufactured by Eli Lilly. Mounjaro was approved by the FDA on May 13, 2022, for type 2 diabetes. Zepbound was approved on November 8, 2023, specifically for chronic weight management. Both come in the same doses (2.5 mg to 15 mg weekly). The main difference is the FDA-approved indication and, in many cases, insurance coverage -- plans may cover one but not the other depending on your diagnosis.

Question 13

How much weight can I lose with tirzepatide (Zepbound)?

Accepted Answer

In the SURMOUNT-1 clinical trial published in the New England Journal of Medicine (2022), participants without type 2 diabetes lost an average of 16.0% of body weight at the 5 mg dose, 21.4% at the 10 mg dose, and 22.5% at the 15 mg dose over 72 weeks. At the highest dose, nearly 40% of participants lost 20% or more of their body weight. Individual results vary based on starting weight, diet, exercise, dose, and other factors.

Question 14

What did the SELECT trial show about semaglutide and heart health?

Accepted Answer

The SELECT trial, published in the New England Journal of Medicine in December 2023, enrolled 17,604 adults with established cardiovascular disease and obesity or overweight (without diabetes). Semaglutide 2.4 mg reduced major cardiovascular events (heart attack, stroke, and cardiovascular death) by 20% compared to placebo (hazard ratio 0.80). Based on these results, the FDA expanded Wegovy's label in March 2024 to include cardiovascular risk reduction.

Question 15

How common is nausea with Wegovy?

Accepted Answer

According to the FDA prescribing information based on the STEP 1 trial, nausea occurred in 44% of patients taking Wegovy 2.4 mg compared to 16% with placebo. However, nausea is typically mild to moderate and tends to decrease over time as the body adjusts. The gradual dose-escalation schedule (starting at 0.25 mg and increasing over 16 weeks to 2.4 mg) is specifically designed to minimize gastrointestinal side effects. About 7% of participants in clinical trials discontinued treatment due to GI side effects.

Question 16

Does Medicare cover GLP-1 weight loss medications?

Accepted Answer

Currently, Medicare Part D is prohibited by the Social Security Act from covering medications prescribed solely for weight loss. However, Medicare does cover GLP-1 medications when prescribed for type 2 diabetes (Ozempic, Mounjaro) or for cardiovascular risk reduction in patients with established CVD and obesity (Wegovy, since March 2024 based on SELECT trial data). Legislative and executive efforts to change the weight loss exclusion are ongoing, and a Medicare GLP-1 Bridge program has been announced.

Question 17

What BMI do I need to qualify for Wegovy or Zepbound?

Accepted Answer

Per FDA-approved labeling, both Wegovy and Zepbound are indicated for adults with a BMI of 30 or higher (obesity), OR a BMI of 27 or higher (overweight) with at least one weight-related comorbid condition such as high blood pressure, type 2 diabetes, or high cholesterol. For reference, a BMI of 30 at 5'8" tall corresponds to approximately 197 pounds. Wegovy is also approved for adolescents aged 12 and older with obesity.

Question 18

What is a GIP/GLP-1 dual agonist?

Accepted Answer

A dual GIP/GLP-1 receptor agonist is a medication that activates two hormone receptors simultaneously: the GIP (glucose-dependent insulinotropic polypeptide) receptor and the GLP-1 (glucagon-like peptide-1) receptor. Tirzepatide (Zepbound, Mounjaro) is currently the only FDA-approved dual agonist. By targeting both receptors, it produces enhanced appetite suppression and metabolic effects compared to GLP-1-only medications. In clinical trials, tirzepatide achieved greater average weight loss than semaglutide (a GLP-1-only agonist).

Question 19

How long does it take to see weight loss results with GLP-1 medications?

Accepted Answer

Most patients begin losing weight within the first few weeks of treatment, though the amount varies during the dose-escalation phase. In the STEP 1 trial, the majority of weight loss with semaglutide occurred during the first 40-50 weeks, after which weight stabilized. Full maintenance dose is typically reached at week 17 for Wegovy and varies for Zepbound depending on tolerability. Clinically meaningful weight loss (5% or more of body weight) is typically achieved within the first 3-4 months at full dose.

Question 20

Can I take GLP-1 medications while pregnant or breastfeeding?

Accepted Answer

No. GLP-1 medications including Wegovy and Zepbound are contraindicated during pregnancy. The FDA prescribing information for Wegovy recommends discontinuing the medication at least 2 months before a planned pregnancy due to its long elimination period. Animal studies have shown potential reproductive harm. If you become pregnant while taking a GLP-1 medication, you should stop the medication and contact your healthcare provider immediately. These medications should also not be used while breastfeeding.

Question 21

How prevalent is obesity in the United States?

Accepted Answer

According to the CDC's National Center for Health Statistics (NCHS Data Brief No. 508), using NHANES data collected between August 2021 and August 2023, 40.3% of U.S. adults age 20 and older have obesity (BMI of 30 or higher). This includes 9.7% with severe obesity (BMI of 40 or higher). In 2024, all 50 U.S. states reported adult obesity prevalence of 25% or higher, with the Midwest having the highest regional rate at 35.9%.

Question 22

What happens if I stop taking GLP-1 medication?

Accepted Answer

Clinical data shows significant weight regain after stopping GLP-1 medications. Extension data from the STEP 1 trial showed that participants who stopped semaglutide regained approximately two-thirds of their lost weight within one year. Metabolic improvements (blood sugar, cholesterol, blood pressure) also partially reversed. This is why current medical guidelines treat obesity as a chronic condition requiring long-term management, similar to how blood pressure medication manages hypertension.

Question 23

What is compounded semaglutide?

Accepted Answer

Compounded semaglutide is a pharmacy-prepared version of the active ingredient found in Wegovy and Ozempic. It is prepared by compounding pharmacies, not the original manufacturer (Novo Nordisk). Compounded semaglutide is not FDA-approved and may be available at lower cost (typically $199-$399 per month compared to $1,349 for brand-name Wegovy). Quality and consistency can vary between compounding pharmacies. The FDA has raised concerns about some compounded GLP-1 products. If considering compounded semaglutide, ensure it comes from a state-licensed compounding pharmacy.

Question 24

What is Saxenda and how does it compare to newer GLP-1 medications?

Accepted Answer

Saxenda (liraglutide 3.0 mg) was the first GLP-1 receptor agonist approved specifically for weight management, receiving FDA approval on December 23, 2014. It requires daily injections (vs. weekly for Wegovy and Zepbound) and produces more modest weight loss -- approximately 8% average weight loss in the SCALE trials compared to approximately 15% with semaglutide and up to 22.5% with tirzepatide. Its manufacturer list price is approximately $1,349 per month. While it has a well-established safety profile, most providers now prefer the newer weekly medications due to greater effectiveness and convenience.

Question 25

Are there oral GLP-1 medications for weight loss?

Accepted Answer

Rybelsus (oral semaglutide) is an oral tablet form of semaglutide approved for type 2 diabetes. An oral version of semaglutide for weight loss received FDA approval in late 2025 at a higher dose, making it the first oral GLP-1 medication approved specifically for weight management. This provides an alternative for patients who prefer not to take weekly injections. Discuss all available options with your healthcare provider to determine which formulation is best for your situation.

GLP-1 Weight Loss: Your Questions Answered

Clinics